"Pharmaceutical Speed Reading Society" Thyda / Lilly double anti-approved clinical medical insurance bureau response to chinese medicine collection ...

December 2, 2020 / Medicines At a Glance: Pfizer/BioNTech's new crown vaccine is the first in the UK to be licensed for emergency use; AstraZenece's $350 million sale of the best-selling cholesterol drug Crestor-related rights; Cinda/Lilly Double Resistance Approved Clinically; and the National Health Insurance Administration responds to the issue of chinese medicine collection... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief The National Health Insurance Administration responded to the issue of Chinese medicine collection on November 30, the National Health Insurance Administration in the "letter on the CPPCC 13th National Committee of the third meeting of the 3181 (medical sports category 459) proposal reply", on the issue of Chinese medicine collection.
include the inclusion of Chinese medicine in the scope of medical insurance payments, the inclusion of Chinese medicine in centralized procurement, the increase in the proportion of medical insurance catalogues above the second level and the proportion of Chinese medicines in the list of essential drugs.
(National Health Insurance Bureau) fraud insurance more than 5000 yuan according to the criminal investigation and prosecution recently, Chongqing Municipal Health Insurance Bureau, the Municipal Public Security Bureau jointly issued "on fraud fraud to obtain medical security fund cases transferred to work notice."
notice clearly, fraud cases transferred illegal amount from 5000 yuan.
six cases, the medical insurance department will be handed over to the public security organs for investigation and prosecution in accordance with criminal offences.
(Chongqing Health Insurance Bureau, Public Security Bureau) Part 2 after observing AstraZeneca's $350 million sale of the best-selling cholesterol drug Crestor rights on December 1st, AstraZeneca announced that it had agreed to sell the statin fat-lowering drug Crestor (rosuvastatin) and related drugs to Grünhalent in more than 30 European countries except the UK and Spain.
(Sina Pharmaceutical News) Novarma sales team major adjustment recently, Novarma released a full mail, from December 1, 2020, the Cardiovascular Division and the Basic Diseases Division merged into a new cardiovascular, kidney and metabolic division, Yan Qiong will be the person in charge.
, Wang Jia will be in charge of integrating the transplant and respiratory teams in the two major diseases and setting up the Transplant and Respiratory Division.
(Seberland) GSK Korea's new CEO arrived on November 30, GlaxoSmithKline said it had appointed Rob Kempton as chief executive.
(Pharmaceutical Representative) Baiji Shenzhou announced the price of the public offering of shareholders today, Baiji Shenzhou announced Baker Bros. Advisors LP Affiliated Fund (Offering Shareholders) prices 1511,546 American Deposital Shares registered for public offering, equivalent to 13 shares of COMMONS at face value of $0.0001 per share, and ADS's public offering at $225 per ADS.
(American News Agency) Alice Pharmaceuticals today officially listed on the Science and Technology Board today, Alice Pharmaceuticals officially landed on the Science and Technology Board.
According to the results of the Ailes Pharmaceuticals issue announcement, the company's share issue price of 22.73 yuan per share, a total size of about 2,045.7 million yuan, the funds raised will be mainly used for new drug research and development, headquarters and research and development base construction.
(Pharmaceutical Mission) Drug Mingkang announced a new generation of ophthalmology gene therapy product production cooperation with ViGeneron On December 1st, Drug Mingkang's CTDMO Drug Mingsheng Foundation, which specializes in cell and gene therapy, announced a strategic partnership with gene therapy company ViGeneron to provide clinical development services for ViGeneron's next-generation ophthalmology gene therapy product VG901.
(Pharmaceutical Mingkangde) Northeast Pharmaceutical Dandong Pharmaceutical illegal sale of inferior drugs by the Liaoning Drug Administration administrative punishment November 30, "Liaoning Provincial Drug Administration Administrative Penalty Results Public" (No. 20 of 2020) shows: It was found that Northeast Pharmaceutical Dandong Pharmaceutical Co., Ltd. sold batch number 518122121 "Injected Ozagre sodium" from April 15, 2019 to October 28, 2019.
Liaoning Drug Administration imposed an administrative penalty on Northeast Pharmaceutical Dandong Pharmaceutical Co., Ltd. and confiscated 3,282 yuan in illegal proceeds.
(Sina Pharmaceutical News) Part 3 Pharmaceutical News Pfizer/BioNTech New Crown Vaccine is the first in the United Kingdom to obtain emergency use authorization Today, Pfizer/BioNTech announced that the Uk Medicines and Health Products Administration has granted its mRNA new crown vaccine BNT162b2 an interim authorization for emergency use, the first country in the world to grant emergency use authorization to BNT162b2.
Phase III study, the second dose of BNT162b2 showed 95 percent protective effect after 7 days of vaccination for people who were not infected or infected with SARS-CoV-2.
(Pharmaceutical Rubik's Cube Info) Novarma/GenenteXolair New Adaptives was approved by the FDA on December 1st, Roche Group member companies Genentek and Novarma Pharmaceuticals simultaneously announced that the FDA has approved the two companies Co-development and commercialization of Xolair® (omalizumab, umamajuumab) supplemental biologics license application for additional maintenance therapy for nasal diapluent in adult patients aged 18 and older who are insensitive to nasal glucosin reactions.
(Xinhua) -- The FDA has accelerated approval of innovative RET inhibitor extension adaptations Today, Blueprint Pharmaceuticals and Geneneck jointly announced that the FDA has accelerated the approval of Gawreto (pralsetinib) extension adaptations for the treatment of thyroid cancer patients with RET variants.
Cornerstone Pharmaceuticals has been awarded a development interest in Pralsetinib in Greater China.
(Pharmaceutical) oral FGFR inhibitors were approved for FDA priority review today, BridgeBio Pharma and its subsidiary QED Therapeutics announced that the FDA has accepted a new drug application for the oral FGFR1-3 selective inhibitor infigratinib for the treatment of bile tube cancer patients.
FDA also granted this NDA priority review eligibility, while using the real-time oncology review pilot project for review.
fda approved the first PSMA targeted PET imaging drug today, the FDA announced, approved by the University of California, Los Angeles and San Francisco jointly developed Ga 68 PSMA-11 listing.
is the first drug approved for electron emission fault scanning imaging of prostate-specific membrane antigen-positive lesions in male prostate cancer patients.
(Drug Mingkangde) Selinexor III Clinical Research SEAL Data released in CTOS 2020 and delivered an oral report on December 1, Deqi Pharmaceuticals announced its strategic partner Karyopharm in CTOS 2020 Release of Selinexor Phase III clinical trial data for the treatment of SEAL in 2020: Selinexor can significantly improve the non-progressive survival of patients with advanced non-removable decissive liposarcoma who have received at least 2 treatment options in the past.
(Pharmaceutical Rubik's Cube) Agios "first-in-class" therapy reaches phase 3 clinical endpoint Today, Agios announced that it is working on the "first-in-class" oral PKR-ensymical activator mitapivat, reaching the main endpoint in a global Phase 3 clinical trial for adult patients with acetone kinase deficiency.
hemoglobin levels in patients treated with mitapivat were statistically significant and sustained compared to placebos.
Agios plans to file regulatory applications with the FDA and the European Union's EMA next year.
(Pharmaceutical Mingkangde) Aachen Pharmaceutical MDM2-p53 inhibitors in the joint Bcl-2 inhibitor Phase 2a clinical study was approved in China and the United States today, Asaan Pharma announced that the company is studying a new class of 1 drug MDM2-p53 inhibitor AP G-115 is licensed for clinical trials of CDE as a single drug or joint Bcl-2 inhibitor APG-2575 and will conduct Phase 2a clinical studies for the treatment of relapsed/difficult-to-treat T-young lymphocytic leukemia (R/R T-PLL).
previously approved clinically by the FDA.
(Pharmaceutical Mission) Shanghai Pharmaceutical Benapri tablets and hydrochloric acid Loxitin intestinal capsule evaluation today, Shanghai Pharmaceuticals announced that its controlling subsidiary New Asia Bank and Shanghai Pharmaceuticals China West respectively received the State Drug Administration issued on the hydrochloric acid Benaspri tablets and hydrochloric acid Loxitin intestinal capsule "Drug Supplemental Application Approval Notice."
is mainly used to treat hypertension, congeal heart failure, hydrochloric acid loxitin intestinal capsules are mainly used to treat depression and so on.
(Sina Pharmaceutical News) Baiji Shenzhou Bcl-2 inhibitors were approved clinically today, CDE official website shows that Baiji Shenzhou BGB-11417 approved clinical, intended for the treatment of mature B-cell malignant tumor BGB-11417 is a Bcl-2 inhibitors, there is no target inhibitors listed in China.
(Insight Database) Hengrui dry eye disease new drug SHR8058 approved clinical today, CDE official website shows that Hengrui pharmaceutical subsidiary eVENUS declared SHR8058 eye drops approved clinical, intended for use in blepharmaceous gland dysfunction-related dry eye disease.
(Insight database) Hengrui Ma-lun 3rd indications newspaper listed today, CDE official website shows that Hengrui submitted the injection of toluene-sulfonate Rema-Lun new indications listing application, and was hosted by CDE.
clinical trials currently under way, the new adaptations listed in this newspaper may be general anaesthetic.
(Insight database) Zhejiang Xianxuan Pharmaceutical Roku bromide injection first review today, NMPA's latest batch of approval shows that Zhejiang Xianxuan Pharmaceutical's Roku Bromine injection won the first review.
roku bromide injection is an analgesic and anesthesiology drug.
(Insight database) Shandong Xinyi Pharmaceutical Apu-lun tablets the first review today, NMPA's latest release of approval shows that Shandong Xinyi Pharmaceutical Apu-lun tablets through consistent evaluation.
tablets are benzodiazepines, which are clinically used to treat insomnia and anxiety.
(Insight Database) Double Crane Pharmaceuticals injection with Pythalmide two sodium review today, NMPA's latest release of approval shows that double crane pharmaceutical injection with pythoncuse two sodium overstatement.
is an anti-folic acid preparation, clinically commonly used in the treatment of non-small cell lung cancer, malignant thoracic mesothelioma.
(Insight database) Shijiazhuang four drugs sodium chloride injection evaluation today, NMPA's latest release of approval shows that Shijiazhuang four drugs hydrochloric acid moxisa star sodium chloride injection evaluation.
is a fourth-generation quinone antibiotic, especially for Streptococcus pneumoniae, which is currently highly resistant.
sodium chloride injections of morphate are currently a first-line drug for multi-clinic anti-infection treatment.
(Insight Database) Tianguang real biological antibody new drug approved clinically in China on December 1, CDE website information shows that Tianguang real organisms recombinant humanized monoclonal antibody MIL62 injection obtained a clinical trial implied permission to develop for lupus nephritis.
(Pharmaceutical Mission) Cyntharma Bio and Lilly jointly developed the PD-1/PD-L1 dual anti-approved clinical CDE website latest publicity, Cynda Bio-declared PD-1/PD-L1 dual specific antibody IBI318 obtained a new clinical trial implied permission to develop the treatment of recurring or refractic NK/T cell lymphoma (nasal type).
(Pharmaceutical Mission) Dongshu medicine 3 new products at the same time into the administrative approval stage recently, Dongshuanglin pharmaceutical 3 copies of the new classification of generic drugs into the administrative approval stage, respectively, Ruishuvastatin calcium tablets, metformin hydrochloride tablets and benzoic acid agritin tablets.
2019, China's public medical institutions and China's urban retail pharmacy terminals, sales of 3 drugs exceeded 7 billion yuan, 3 billion yuan, 100 million yuan, respectively.
(Mienet)